Jelle Wesseling

Jelle Wesseling

Auto-generated profile, based on publicly available information

Jelle Wesseling

Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2014 in Nature
Verified
Journal Article
Closed access
PDF file
CSChong Sun
Chong Sun
LWLiqin Wang
Liqin Wang
SHSidong Huang
Sidong Huang
GHGuus J. J. E. Heynen
Guus J. J. E. Heynen
APAnirudh Prahallad
Anirudh Prahallad
RBRené Bernards
René Bernards

25 May 2010 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
FBFiona M. Blows
Fiona M. Blows
KDKristy E. Driver
Kristy E. Driver
Marjanka SchmidtMarjanka Schmidt
Marjanka Schmidt
ABAnnegien Broeks
Annegien Broeks
FLFlora E. van Leeuwen
Flora E. van Leeuwen
DHDavid Huntsman
David Huntsman
Immunohistochemical markers are often used to classify breast cancer into subtypes that are biologically distinct and behave differently. The aim of this study was to estimate mortality for patients with the major subtypes of breast cancer as classified using five immunohistochemical markers, to investigate patterns of mortality over time, and to test for heterogeneity by subtype. We pooled data from more than 10,000 cases of invasive breast cancer from 12 studies that had collected information on hormone receptor status, human epidermal growth factor receptor-2 (HER2) status, and at least one basal marker (cytokeratin [CK]5/6 or epidermal growth factor receptor [EGFR]) together with survival time data. Tumours were classified as luminal and nonluminal tumours according to hormone receptor expression. These two groups were further subdivided according to expression of HER2, and finally, the luminal and nonluminal HER2-negative tumours were categorised according to expression of basal markers. Changes in mortality rates over time differed by subtype. In women with luminal HER2-negative subtypes, mortality rates were constant over time, whereas mortality rates associated with the luminal HER2-positive and nonluminal subtypes tended to peak within 5 y of diagnosis and then decline over time. In the first 5 y after diagnosis the nonluminal tumours were associated with a poorer prognosis, but over longer follow-up times the prognosis was poorer in the luminal subtypes, with the worst prognosis at 15 y being in the luminal HER2-positive tumours. Basal marker expression distinguished the HER2-negative luminal and nonluminal tumours into different subtypes. These patterns were independent of any systemic adjuvant therapy. The six subtypes of breast cancer defined by expression of five markers show distinct behaviours with important differences in short term and long term prognosis. Application of these markers in the clinical setting could have the potential to improve the targeting of adjuvant chemotherapy to those most likely to benefit. The different patterns of mortality over time also suggest important biological differences between the subtypes that may result in differences in response to specific therapies, and that stratification of breast cancers by clinically relevant subtypes in clinical trials is urgently required. Please see later in the article for the Editors' Summary

1 December 2018 in The Lancet Oncology
Verified
Journal Article
Closed access
MRMette S van Ramshorst
Mette S van Ramshorst
AVAnna van der Voort
Anna van der Voort
EWErik Van Werkhoven
Erik Van Werkhoven
IMIngrid A Mandjes
Ingrid A Mandjes
IKInge Kemper
Inge Kemper
GSGabe S Sonke
Gabe S Sonke

1 February 2015 in Annals of Surgery
Verified
Journal Article
Closed access
MDMila Donker
Mila Donker
MSMarieke E. Straver
Marieke E. Straver
JWJelle Wesseling
Jelle Wesseling
CLClaudette E. Loo
Claudette E. Loo
MSMargaret Schot
Margaret Schot
MPMarie-Jeanne T. F. D. Vrancken Peeters
Marie-Jeanne T. F. D. Vrancken Peeters
The MARI procedure [marking the axillary lymph node with radioactive iodine (I) seeds] is a new minimal invasive method to assess the pathological response of nodal metastases after neoadjuvant systemic treatment (NST) in patients with breast cancer. This method allows axilla-conserving surgery in patients responding well to NST. Prior to NST, proven tumor-positive axillary lymph nodes were marked with a I seed. This marked lymph node is the so-called MARI-node. After NST, the MARI node was selectively removed using a γ-detection probe. A complementary axillary lymph node dissection was performed in all patients to assess whether pathological response in the MARI node was indicative for the pathological response in the additional lymph nodes. A tumor-positive axillary lymph node was marked with a I seed in 100 patients. The MARI node was successfully identified in 97 of these 100 patients (identification rate 97%). Two patients did not undergo subsequent axillary lymph node dissection, leaving 95 patients for further analysis. The MARI node contained residual tumor cells in 65 of these 95 patients. In the other 30 patients, the MARI node was free of tumor, but additional positive lymph nodes were found in 5 patients. Thus, the MARI procedure correctly identified 65 of 70 patients with residual axillary tumor activity (false negative rate 5/70 = 7%). This study shows that marking and selectively removing metastatic lymph nodes after neoadjuvant systemic treatment has a high identification rate and a low false negative rate. The tumor response in the marked lymph node may be used to tailor further axillary treatment after NST.

23 October 2017 in Nature Genetics
Verified
Journal Article
Open access
PDF file
AIABCTB Investigators
ABCTB Investigators
RMRoger L Milne
Roger L Milne
EMEmbrace
Embrace
GCGEMO Study Collaborators
GEMO Study Collaborators
HEHebon
Hebon
JSJacques Simard
Jacques Simard
Roger Milne and colleagues conduct a genome-wide association study for estrogen receptor (ER)-negative breast cancer combined with BRCA1 mutation carriers in a large cohort. They identify ten new risk variants and find high genetic correlation between breast cancer risk for BRCA1 mutation carriers and risk of ER-negative breast cancer in the general population. Most common breast cancer susceptibility variants have been identified through genome-wide association studies (GWAS) of predominantly estrogen receptor (ER)-positive disease1. We conducted a GWAS using 21,468 ER-negative cases and 100,594 controls combined with 18,908 BRCA1 mutation carriers (9,414 with breast cancer), all of European origin. We identified independent associations at P < 5 × 10−8 with ten variants at nine new loci. At P < 0.05, we replicated associations with 10 of 11 variants previously reported in ER-negative disease or BRCA1 mutation carrier GWAS and observed consistent associations with ER-negative disease for 105 susceptibility variants identified by other studies. These 125 variants explain approximately 16% of the familial risk of this breast cancer subtype. There was high genetic correlation (0.72) between risk of ER-negative breast cancer and breast cancer risk for BRCA1 mutation carriers. These findings may lead to improved risk prediction and inform further fine-mapping and functional work to better understand the biological basis of ER-negative breast cancer.

18 June 2020 in Nature Reviews Clinical Oncology
Verified
Journal Article
Open access
PDF file
NPNora Pashayan
Nora Pashayan
AAAntonis C. Antoniou
Antonis C. Antoniou
UIUrska Ivanus
Urska Ivanus
LELaura J. Esserman
Laura J. Esserman
DEDouglas F. Easton
Douglas F. Easton
MWMartin Widschwendter
Martin Widschwendter
The European Collaborative on Personalized Early Detection and Prevention of Breast Cancer (ENVISION) brings together several international research consortia working on different aspects of the personalized early detection and prevention of breast cancer. In a consensus conference held in 2019, the members of this network identified research areas requiring development to enable evidence-based personalized interventions that might improve the benefits and reduce the harms of existing breast cancer screening and prevention programmes. The priority areas identified were: 1) breast cancer subtype-specific risk assessment tools applicable to women of all ancestries; 2) intermediate surrogate markers of response to preventive measures; 3) novel non-surgical preventive measures to reduce the incidence of breast cancer of poor prognosis; and 4) hybrid effectiveness–implementation research combined with modelling studies to evaluate the long-term population outcomes of risk-based early detection strategies. The implementation of such programmes would require health-care systems to be open to learning and adapting, the engagement of a diverse range of stakeholders and tailoring to societal norms and values, while also addressing the ethical and legal issues. In this Consensus Statement, we discuss the current state of breast cancer risk prediction, risk-stratified prevention and early detection strategies, and their implementation. Throughout, we highlight priorities for advancing each of these areas.